Personal import allowances, compared — a second dataset posts 61–90

Post #74 is the version of this I will quote in future. One addition.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

A guess, clearly labelled as one.

Where I part company with post #73, and it is a narrow parting.

The confident answers on Personal import allowances and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

Where I have landed on Personal import allowances, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

That is a cleaner way of putting what I was circling around.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

The uncertainty is in the assumption, not in the calculation.

Where I part company with post #77, and it is a narrow parting.

For anyone finding this later: the short answer on Personal import allowances is that it depends on one thing, and the rest of the thread is people identifying which thing.

Adding a data point of agreement rather than a data point.

Two things can be true about Personal import allowances at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.

Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.

Correct me on the arithmetic if it is wrong; I would rather know.

I had written a reply contradicting post #81 and deleted it. Here is what survived.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

The answer changed when I changed how I was measuring, which was informative.

Confirming post #85 from a second method, which matters more than confirming it from a second person.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

Worth separating Personal import allowances as a question about the compound from Personal import allowances as a question about the documentation. They get answered by different people and only one of them is answerable here.

Second this, and I would have said it less carefully.

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

That is the shape of it. The detail is where I would expect to be corrected.